Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2 diabetes, according to a study ...

In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora, administered in a fixed-dose regimen, was noninferior to once-daily glargine in reducing glycated ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in managing blood sugar levels among adults with type 2 diabetes, according to ...

In QWINT-3, the respective rates were 0.84 for efsitora and 0.74 for insulin degludec at 78 weeks. In QWINT-4, the rates were 6.6 for efsitora and 5.9 for insulin glargine at 26 weeks.

Biocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of ...

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.